All In Biotech

Drug Trial Radar · NCT04630353

A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

A Phase 0 Trial of HB-201 for Subjects With Transoral Resectable Human Papillomavirus 16 Positive (HPV 16+) Oropharynx Cancer or With Locally Advanced Cervical Cancer Treated With Chemotherapy and Radiation

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

10

Actual

Start

Jul 21, 2021

Primary completion

Nov 28, 2023

Study completion Nov 28, 2023

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Hookipa Biotech GmbH
First posted
Nov 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Window of Opportunity clinical trial will examine the immunologic effects of the study agent HB-201 in the head and neck or cervical cancer, when administered by IV route.

Conditions

  • HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer

Interventions

  • HB-201 IVDrug

    HB-201 given IV, one (1) time, on day 1.

  • HB-201 IVDrug

    HB-201 given IV, one (1) time, 7 to 14 days prior to definitive chemoradiation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Immune response profiles in subjects with HPV 16+ Head and Neck and cervical cancer.Time frame: Approximately 6-8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.